Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.
Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.
Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.
Capricor Therapeutics (NASDAQ: CAPR) reported significant advancements in its therapy programs for Duchenne muscular dystrophy (DMD) and COVID-19. After a successful end-of-phase-II meeting with the FDA, Capricor plans to initiate a Phase III pivotal trial for CAP-1002 for DMD. Financially, the company achieved approximately $200,000 in revenues, up from $50,000 year-over-year. However, operating expenses rose to $5.3 million, resulting in a net loss of $4.7 million. Their cash reserves increased to $38.1 million, projected to fund operations for at least two years.
Capricor Therapeutics (NASDAQ: CAPR) will release its Q2 2021 financial results on August 12, 2021, after market close. Following this, a webcast and conference call will occur at 4:30 p.m. ET to discuss the results and provide a corporate update. Capricor focuses on developing cell and exosome-based therapeutics for various diseases, including Duchenne muscular dystrophy and COVID-19 related conditions. The lead candidate, CAP-1002, is currently in clinical development.
Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a study showing that cardiosphere-derived exosomes (CDC-EVs) can reduce kidney damage and enhance blood vessel formation in a preclinical acute trauma model. This research, in collaboration with the USA Army Institute of Surgical Research, indicates CDC-EVs as a potential antishock therapeutic, highlighting their ease of use in field situations. Capricor is also actively enrolling patients in a Phase II study for CAP-1002 to treat severe COVID-19, emphasizing the broader therapeutic potential of their exosome technology.
Capricor Therapeutics (NASDAQ: CAPR) has appointed Karimah Es Sabar to its Board of Directors, effective immediately. With over 35 years of experience in the life sciences industry, Es Sabar brings substantial expertise in business development and strategic collaborations. CEO Linda Marbán expressed optimism about her contributions, citing her successful track record in launching first-in-class vaccines. Capricor focuses on innovative therapies, including its CAP-1002 cell therapy for Duchenne muscular dystrophy and exosome technologies aimed at treating various diseases. This leadership change marks a significant step in Capricor's growth strategy.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Linda Marbán will present updates on the Phase II HOPE-2 trial of CAP-1002 at the PPMD 2021 Virtual Annual Conference on June 23. The ongoing open-label extension study allows eligible patients to receive CAP-1002 after completing a year-long trial. The panel will discuss therapies to protect muscles in Duchenne muscular dystrophy, affecting one in 3,600 male births globally. CAP-1002 is currently in development and aims to improve treatment outcomes for this condition.
Capricor Therapeutics (NASDAQ: CAPR) announced its participation in 1x1 investor meetings at the BIO Digital 2021 conference occurring from June 10-11 and June 14-18, 2021. The company focuses on developing cell and exosome-based therapeutics for various diseases, including its lead candidate, CAP-1002, for Duchenne muscular dystrophy and COVID-19 cytokine storms. Investors can schedule meetings via the BIO Digital partnering system and access materials in the Investor Relations section of Capricor's website.
Capricor Therapeutics (NASDAQ: CAPR) presented findings on its exosome-mediated mRNA delivery approach for SARS-CoV-2 at the ISEV Annual Meeting, highlighting its potential to address challenges posed by COVID-19 variants. CEO Linda Marbán noted that their multivalent mRNA vaccine generates lasting immune responses. This data emphasizes Capricor's innovative platform, which aims to deliver targeted therapies across various diseases. The meeting runs from May 18-21, 2021, with on-demand access to sessions until June 14, 2021.
Capricor Therapeutics (NASDAQ: CAPR) announced significant developments in the first quarter of 2021, including a net loss of $5.2 million. The company executed a licensing agreement with Johns Hopkins University, advancing its engineered exosome technology. Capricor plans to file an IND for its SARS-CoV-2 vaccine and expects top-line data from its INSPIRE clinical trial by Q3 2021. The company raised $12.6 million through stock offerings and reported cash reserves of approximately $41.9 million, which should suffice to cover expenses through at least Q2 2023.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Linda Marbán, Ph.D., will present at the ASGCT's 24th annual meeting, held virtually from May 11-14, 2021. The session, titled Therapeutic Applications of Extracellular Vesicles, focuses on exosome delivery of SARS-CoV-2 vaccines. Marbán emphasized the company's leadership in exosome delivery for COVID-19 vaccination. Capricor is known for developing cell- and exosome-based therapeutics, including its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy and COVID-19 related cytokine storms.
Capricor Therapeutics (NASDAQ: CAPR) will announce its financial results for Q1 2021 on May 13, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the financial performance and recent corporate updates. Capricor focuses on cell- and exosome-based therapies, particularly its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy and cytokine storms in COVID-19 patients. The company is also advancing its exosome platform technology for various diseases.
